Geneos Wealth Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-50
Closed -$588 2538
2025
Q4
$588 Buy
+50
New +$539 ﹤0.01% 2449
2025
Q1
Sell
-50
Closed -$824 3119
2024
Q4
$824 Hold
50
﹤0.01% 2812
2024
Q3
$738 Hold
50
﹤0.01% 2499
2024
Q2
$694 Hold
50
﹤0.01% 2022
2024
Q1
$786 Hold
50
﹤0.01% 2072
2023
Q4
$809 Hold
50
﹤0.01% 2041
2023
Q3
$615 Hold
50
﹤0.01% 2081
2023
Q2
$804 Hold
50
﹤0.01% 2037
2023
Q1
$871 Buy
+50
New +$712 ﹤0.01% 2004
2022
Q2
Sell
-50
Closed 2718
2022
Q1
$0 Buy
+50
New +$1.05K ﹤0.01% 2905
2021
Q2
Sell
-50
Closed -$2K 3024
2021
Q1
$2K Buy
+50
New +$2.6K ﹤0.01% 2908
2020
Q2
Sell
-500
Closed -$12K 2599
2020
Q1
$12K Sell
500
-500
-50% -$15K ﹤0.01% 1732
2019
Q4
$29K Hold
1,000
﹤0.01% 1523
2019
Q3
$19K Buy
1,000
+400
+67% +$9.38K ﹤0.01% 1635
2019
Q2
$13K Buy
+600
New +$13.2K ﹤0.01% 1814
2017
Q3
Sell
-200
Closed -$1K 2135
2017
Q2
$1K Hold
200
﹤0.01% 2015
2017
Q1
$1K Hold
200
﹤0.01% 2004
2016
Q4
$1K Sell
200
-500
-71% -$4.28K ﹤0.01% 1974
2016
Q3
$5K Buy
700
+500
+250% +$4.2K ﹤0.01% 1578
2016
Q2
$1K Hold
200
﹤0.01% 1756
2016
Q1
$1K Buy
+200
New +$1.32K ﹤0.01% 1737

Other funds holding NEO

Geneos Wealth Management's NEO Position: Q1 2026 in Review

Geneos Wealth Management sold out of NeoGenomics (NEO) in Q1 2026, closing a stake of 50 shares — an estimated $588 sold.

Geneos Wealth Management first reported a position in NEO in Q1 2016 and held it in 21 quarters. The position peaked at $29K in Q4 2019. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

  • Geneos Wealth Management reported no remaining NeoGenomics position as of Q1 2026 after selling out during the quarter.
  • Geneos Wealth Management sold 50 NeoGenomics shares in Q1 2026, an estimated $588.
  • Geneos Wealth Management first reported a position in NeoGenomics in Q1 2016 and held it in 21 quarters.
  • Geneos Wealth Management's NeoGenomics position peaked at $29K in Q4 2019.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.